While currently indicated for testing in breast invasive carcinoma only, PIK3CA mutations were present across multiple tumor types, suggesting that clinical trials with PIK3CA inhibitors could be considered in the future, if clinically appropriate. Here, PIK3CA is linked to invasive breast carcinoma.